Texas Biomedical Research Institute. Texas Biomedical Research Institute is the only privately-owned facility that has both BSL3 and BSL4 in the United States.
3V Medical Research Group, developed a targeted therapeutic therapy treatment for SARs CoV-2 infection and Influenza.
3V Medical preformed in vitro and in vivo studies at Texas Biomedical Research Institute located in San Antonio, Texas.
OBJECTIVE:
The purpose of this study is to assess the effect of 3VM1000 Suspension on SAR CoV-2 infectivity of host cells in vitro. Pre-challenge study to determine if 3VM100 Suspension is effective in killing SARS-CoV-2 and reduce its infectivity in vitro.
SOW (Click here)
Final In Vitro Study test report (Click here)
OBJECTIVE:
This study is designed to test in vivo toxicity and efficacy of 3VM-1000 suspension in a mouse
model of SARS-CoV-2 infection by measuring the viral load and survival. To determine the anti-SARS-CoV-2 effect of 3VM-1000 suspension in K18 hACE-2 mice.
Aim 1: To determine in vivo toxicity of 3VM-1000 suspension solution in K18-hACE-2 mice
SOW (click here)
Final Results (click here)
Aim 2: In vivo assessment of 3VM-1000 suspension on SARS-CoV-2 infectivity
Currently, Texas Biomedical Research Institute is conducting Aim 2 study using 3VM-1000 suspension solution for the effectiveness to treat SARS-CoV2.